GLPwatch
Papers (12034)
Page 32 of 201, ranked by citation count.
- Exendin-4 and eldecalcitol synergistically promote osteogenic differentiation of bone marrow mesenchymal stem cells through M2 macrophages polarization via PI3K/AKT pathway.
- The role of glucagon-like peptide-1 receptor (GLP-1R) agonists in enhancing endothelial function: a potential avenue for improving heart failure with preserved ejection fraction (HFpEF).
- A systematic review of GLP-1 agonists on the metabolic syndrome in women with polycystic ovaries.
- Predicted structure of agonist-bound glucagon-like peptide 1 receptor, a class B G protein-coupled receptor.
- Independent glucose and weight-reducing effects of Liraglutide in a real-world population of type 2 diabetic outpatients.
- The effects of glucagon-like peptide 1 receptor agonist (exenatide) on memory impairment, and anxiety- and depression-like behavior induced by REM sleep deprivation.
- Preservation of the blood brain barrier and cortical neuronal tissue by liraglutide, a long acting glucagon-like-1 analogue, after experimental traumatic brain injury.
- Effects of Sustained Treatment With Lixisenatide on Gastric Emptying and Postprandial Glucose Metabolism in Type 2 Diabetes: A Randomized Controlled Trial.
- Effects of liraglutide, a human glucagon-like peptide-1 analogue, on body weight, body fat area and body fat-related markers in patients with type 2 diabetes mellitus.
- Residues within the transmembrane domain of the glucagon-like peptide-1 receptor involved in ligand binding and receptor activation: modelling the ligand-bound receptor.
- Liraglutide for Weight Management in Children and Adolescents With Prader-Willi Syndrome and Obesity.
- Systolic blood pressure reduction with tirzepatide in patients with type 2 diabetes: insights from SURPASS clinical program.
- Effects of liraglutide on gallbladder emptying: A randomized, placebo-controlled trial in adults with overweight or obesity.
- Effect of exenatide on splanchnic and peripheral glucose metabolism in type 2 diabetic subjects.
- An evaluation of liraglutide including its efficacy and safety for the treatment of obesity.
- Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly, or dapagliflozin, added to metformin monotherapy, on body weight, systolic blood pressure, and triglycerides in patients with type 2 diabetes in the DURATION-8 study.
- Pharmacological characterization of mono-, dual- and tri-peptidic agonists at GIP and GLP-1 receptors.
- Effectiveness and tolerability of liraglutide in patients with type 2 diabetes mellitus and obesity after bariatric surgery.
- Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk factors: A narrative review of head-to-head comparisons.
- The potential role of incretin-based therapies for polycystic ovary syndrome: a narrative review of the current evidence.
- Effect of Exendin-4 on Autophagy Clearance in Beta Cell of Rats with Tacrolimus-induced Diabetes Mellitus.
- Effects of metformin and Exenatide on insulin resistance and AMPKα-SIRT1 molecular pathway in PCOS rats.
- Liraglutide in the management of type 2 diabetes.
- The role of GLP-1 mimetics and basal insulin analogues in type 2 diabetes mellitus: guidance from studies of liraglutide.
- Shorter-acting glucagon-like peptide-1 receptor agonists are associated with increased development of gastro-oesophageal reflux disease and its complications in patients with type 2 diabetes mellitus: a population-level retrospective matched cohort study.
- Spinal microglial β-endorphin signaling mediates IL-10 and exenatide-induced inhibition of synaptic plasticity in neuropathic pain.
- Exenatide treatment increases serum irisin levels in patients with obesity and newly diagnosed type 2 diabetes.
- Efficacy and Safety of Once-Weekly Semaglutide for the Treatment of Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
- GLP-1 receptor agonists and the risk for cancer: A meta-analysis of randomized controlled trials.
- Reversal of Long-Term Weight Regain After Roux-en-Y Gastric Bypass Using Liraglutide or Surgical Revision. A Prospective Study.
- GLP-1R agonist therapy for diabetes: benefits and potential risks.
- Glucagon-like peptide 1 receptor agonists in type 1 diabetes mellitus.
- Effect of exenatide twice daily and dapagliflozin, alone and in combination, on markers of kidney function in obese patients with type 2 diabetes: A prespecified secondary analysis of a randomized controlled clinical trial.
- Liraglutide induces beige fat development and promotes mitochondrial function in diet induced obesity mice partially through AMPK-SIRT-1-PGC1-α cell signaling pathway.
- Glucagon-like peptide 1 inhibits the sirtuin deacetylase SirT1 to stimulate pancreatic β-cell mass expansion.
- Effects of liraglutide in hypothalamic arcuate nucleus of obese mice.
- Sustained Release Strategy Designed for Lixisenatide Delivery to Synchronously Treat Diabetes and Associated Complications.
- Exendin-4 protects hypoxic islets from oxidative stress and improves islet transplantation outcome.
- The glucagon-like peptide-1 receptor agonist exendin-4 ameliorates warfarin-associated hemorrhagic transformation after cerebral ischemia.
- No evidence of drug-induced pancreatitis in rats treated with exenatide for 13 weeks.
- Empagliflozin and Dulaglutide are Effective against Obesity-induced Airway Hyperresponsiveness and Fibrosis in A Murine Model.
- Alzheimer's disease and diabetes: new insights and unifying therapies.
- Cooperative role of the glucagon-like peptide-1 receptor and β3-adrenergic-mediated signalling on fat mass reduction through the downregulation of PKA/AKT/AMPK signalling in the adipose tissue and muscle of rats.
- Exogenous peptide YY3-36 and Exendin-4 further decrease food intake, whereas octreotide increases food intake in rats after Roux-en-Y gastric bypass.
- Tirzepatide Associated With Reduced Albuminuria in Participants With Type 2 Diabetes: Pooled Post Hoc Analysis From the Randomized Active- and Placebo-Controlled SURPASS-1-5 Clinical Trials.
- One-year treatment with liraglutide improved renal function in patients with type 2 diabetes: a pilot prospective study.
- Mechanism of the neuroprotective effect of GLP-1 in a rat model of Parkinson's with pre-existing diabetes.
- Exenatide and sitagliptin are not associated with increased risk of acute renal failure: a retrospective claims analysis.
- Short term effects of semaglutide on emotional eating and other abnormal eating patterns among subjects living with obesity.
- Coating of PLA-nanoparticles with cyclic, arginine-rich cell penetrating peptides enables oral delivery of liraglutide.
- Semaglutide Treatment of Excessive Body Weight in Obese PCOS Patients Unresponsive to Lifestyle Programs.
- Topical ocular administration of the GLP-1 receptor agonist liraglutide arrests hyperphosphorylated tau-triggered diabetic retinal neurodegeneration via activation of GLP-1R/Akt/GSK3β signaling.
- Glucagon-like peptide-1 receptor agonists reverse nerve morphological abnormalities in diabetic peripheral neuropathy.
- Differentiating effects of the glucagon-like peptide-1 analogue exendin-4 in a human neuronal cell model.
- The Effectiveness of GLP-1 Receptor Agonist Semaglutide on Body Composition in Elderly Obese Diabetic Patients: A Pilot Study.
- Efficacy of antihyperglycemic therapies and the influence of baseline hemoglobin A(1C): a meta-analysis of the liraglutide development program.
- Site-specific PEGylation of exenatide analogues markedly improved their glucoregulatory activity.
- Exposure-response analysis for evaluation of semaglutide dose levels in type 2 diabetes.
- Liraglutide in mild to moderate Alzheimer's disease: a phase 2b clinical trial.
- GLP-1-RA Corrects Mitochondrial Labile Iron Accumulation and Improves β-Cell Function in Type 2 Wolfram Syndrome.